Ionis Pharmaceuticals (IONS) Return on Capital Employed (2010 - 2026)

Ionis Pharmaceuticals' Return on Capital Employed history runs 17 years deep, the most recent figure standing at 12.72% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 506.0% year-over-year to 12.72%; the TTM figure through Mar 2026 stood at 12.72% (up 506.0% YoY), while the FY2025 annual figure was 3.21%, up 38.0% from the prior year.
• Return on Capital Employed was 12.72% for Q1 2026 at Ionis Pharmaceuticals, up from 15.29% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 0.86% in Q3 2022 to a low of 21.8% in Q3 2023.
• Historically, Return on Capital Employed has averaged 13.26% across 5 years, with a median of 15.07% in 2024.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed soared 1342 bps in 2022, then slumped 2266 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 18.93% in 2022, then climbed by 26 bps to 14.07% in 2023, then declined by 24 bps to 17.38% in 2024, then gained by 12 bps to 15.29% in 2025, then climbed by 17 bps to 12.72% in 2026.
• The last three Return on Capital Employed figures came in at 12.72% (Q1 2026), 15.29% (Q4 2025), and 13.2% (Q3 2025), per Business Quant data.